Literature DB >> 3994441

Risk factors for survival following surgical treatment of traumatic aortic rupture.

J T Sturm, T R Billiar, J S Dorsey, M G Luxenberg, J F Perry.   

Abstract

Linear discriminate analysis was used to determine the effects of age and Injury Severity Score on survival in 37 consecutive patients treated surgically for traumatic rupture of the thoracic aorta. Pearson product moment correlations were calculated between associated injuries and survival. The age of the injured patients was the only variable that correlated statistically with survival: the lower the patient's age, the greater the chance of survival (r = 0.3535; p = 0.016). The severity of the injury, as represented by the Injury Severity Score, showed a tendency toward decreased survival with increasing Injury Severity Score (r = -0.2523; p = 0.066). Specific types of associated injuries did not correlate with survival. Survival rates were not statistically different for patients who underwent cardiopulmonary bypass compared with those in whom a temporary plastic shunt was used (chi-square = 1.72; p = 0.19). We conclude that age is the most significant factor in predicting survival in patients who undergo surgical repair of traumatic aortic rupture.

Entities:  

Mesh:

Year:  1985        PMID: 3994441     DOI: 10.1016/s0003-4975(10)61947-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  The widened mediastinum. Diagnostic and therapeutic priorities.

Authors:  J D Richardson; M E Wilson; F B Miller
Journal:  Ann Surg       Date:  1990-06       Impact factor: 12.969

2.  Surgical management of traumatic disruption of the descending aorta.

Authors:  J N Young; R J Stallone; L I Iverson; C L Ennix; R R Ecker; I A May
Journal:  West J Med       Date:  1989-06

Review 3.  Endovascular Repair of Traumatic Isthmic Ruptures: Special Concerns.

Authors:  Nikolaos Patelis; Athanasios Katsargyris; Chris Klonaris
Journal:  Front Surg       Date:  2017-06-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.